Azithromycin for acute wheezing and bronchiolitis in children younger than six years: A systematic review and meta-analysis.

Authors

Douglas Amaral da Silva Menegazzo Miotto, Isabela Ovídio Ramos, Caroline Molina Grassi

Published in

Paediatric respiratory reviews. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Azithromycin is often prescribed off-label for acute wheezing and bronchiolitis in young children, despite guideline advice against routine antibiotics. We synthesised the randomised evidence and tested whether benefit depends on care setting.
We searched four databases and two registries to June 2026 for double-blind, placebo-controlled trials of azithromycin versus placebo in children younger than six years with acute wheezing or bronchiolitis. The acute episode was pooled as the ratio of means and binary outcomes as risk ratios (random-effects models).
Ten trials (2,071 children) were included. In emergency-department and ward patients, azithromycin had no effect on the acute episode (ratio of means 0.99, 95 % CI 0.96-1.04; I²=0 %) and did not reduce hospitalisation or recurrent wheeze. Apparent benefit was confined to intensive-care and home-treated recurrent episodes (between-subgroup p<0.0001).
Azithromycin does not help children with acute wheezing or bronchiolitis where it is used; routine use is not supported.

PMID:
42881103
Bibliographic data and abstract were imported from PubMed on 16 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.